4.74
-0.16
(-3.27%)
May 17 - Close
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 4.71 - 4.95 |
| 52 week | 3.12 - 6.89 |
| Open | 4.89 |
| Vol / Avg. | 281,806.00/230,403.00 |
| Mkt cap | 192.95M |
| P/E | - |
| Div/yield | - |
| EPS | -0.54 |
| Shares | 40.71M |
| Beta | 1.76 |
| Inst. own | 63% |
Events
May 14, 2013
BIODELIVERY SCIENCES INTL INC at Bank of America Merrill Lynch Health Care Conference
Mar 18, 2013
BIODELIVERY SCIENCES INTL INC at Roth Conference
Mar 7, 2013
BIODELIVERY SCIENCES INTL INC Analyst Meeting
Mar 5, 2013
BIODELIVERY SCIENCES INTL INC at Cowen Health Care Conference
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | -784.39% | 3.03% |
| Operating margin | -845.38% | 12.95% |
| EBITD margin | - | 15.67% |
| Return on average assets | -74.21% | 3.32% |
| Return on average equity | -114.06% | 6.13% |
| Employees | 21 | - |
| Carbon Disclosure Rating | - | - |
Address
Suite 210 801 Corporate Center Drive
RALEIGH, NC 27607
United States - Map
+1-919-5829050 (Phone)
+1-919-5829051 (Fax)
RALEIGH, NC 27607
United States - Map
+1-919-5829050 (Phone)
+1-919-5829051 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
BioDelivery Sciences International, Inc. (BDSI) is a specialty pharmaceutical company. BDSI is developing and commercializing, either on its own or in partnerships with third parties, applications of therapeutics to address medical needs. The Company has developed and is continuing to develop pharmaceutical products aimed principally in the areas of pain management and oncology supportive care. In formulating the Company's products and product candidates, BDSI utilizes the BioErodible MucoAdhesive (BEMA) drugs delivery technology, a small, erodible polymer film for application to the buccal mucosa. The Company's the United Sates Food and Drug Administration (FDA) approved product, ONSOLIS (fentanyl buccal soluble film), as well as its pipeline of product candidates, utilize its BEMA technology.
Officers and directors
| Francis E. O'Donnell Jr., M.D. | Executive Chairman of the Board | |
| Mark A. Sirgo Pharm.D. | President, Chief Executive Officer, Director | |
| James A. McNulty CPA | Chief Financial Officer, Treasurer, Secretary | |
| Andrew L. Finn Pharm.D. | Executive Vice President - Product Development | |
| William B. Stone | Lead Independent Director | |
| Thomas W. D'Alonzo | Director | |
| William S. Poole | Independent Director | |
| Samuel P. Sears Jr. | Independent Director | |
| John J. Shea | Independent Director |